Moderna stock soared early in the pandemic thanks to sales of its coronavirus vaccine. After soaring to success in the early ...

The Department of Health and Human Services has defended cuts to vaccine research with statements that mislead on the safety ...

The FDA expanded its approval of Moderna's RSV vaccine on Thursday to include adults under age 60 at increased risk of the disease.

Moderna vaulted to the forefront of biotech, becoming a major pillar of the region’s economy. But Robert F. Kennedy Jr.’s ...

The main reason for the downturn in Moderna’s stock is a significant drop in the demand for its COVID-19 vaccine.

The Food and Drug Administration (FDA) has approved Moderna’s next-generation mRNA COVID-19 vaccine mNexspike ®.

Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged 60 and older CAMBRIDGE, MA / ACCESS ...

The agency’s decision to clear Moderna’s shot for use in certain younger adults is a much-needed win for a company that’s ...

(HealthDay News) — The U.S. Food and Drug Administration has approved a new lower-dose vaccine for active immunization against COVID-19 caused by severe acute respiratory syndrome coronavirus 2.

Interest in what caused the coronavirus pandemic has many political dimensions today, with President Trump saying genetic ...